A unique range of integrated early stage development services to support biopharmaceutical drug development.
Cell Line Development
Upstream Process Development
Cell Bank Manufacturing
Cell Bank Characterisation
GMP Lot Release
Solutions through experience
This extensive suite of services combines Cellca’s cell line and upstream process development expertise with BioOutsource’s bioanalytical and biosafety contract testing expertise to support customers from cell line development, through product manufacture and release. Broadening Sartorius Stedim Biotech’s portfolio of products, technologies and services and enabling a comprehensive “Total Solution” to support our clients’ drug development activities.
Benefit from the combined experience of Cellca, BioOutsource and Sartorius Stedim Biotech to efficiently advance your drug candidates quickly from early stage development through to commercialisation.
Accelerated drug development
Based on its unparalleled global experience working to support biological drug development, BioOutsource and Cellca lead the way in preclinical development. Through our robust platforms, off-the-shelf assays and commitment to providing a total solution, Sartorius Stedim Biotech can accelerate your drug’s development.
BioOutsource and Cellca have industry leading expertise in supporting biosimilar drug development. Collectively we have worked with over 50 biosimilar developers across 12 countries, totalling 230 biosimilar projects. Benefit from our combined experience and integrated services to further mitigate risks and select optimal biosimilar clones. Find out more.
Our service offering is underpinned by our commitment to delivering excellent customer service, navigating our customers through the complexities of the drug development cycle and enabling them to make informed data-driven decisions. Our client management team provide an intimate customer experience and ensure your project is managed efficiently and delivered on time. Effective communication is key to success, and our team understand that a transparent, proactive approach to customer service will ensure the delivery of a truly differentiated solution.
Contact our experts today to discuss your drug development programmes.
• Biopharma provider purchases property in Science Park III of Ulm • Laboratory and office facility to be constructed on the site by 2019 Göttingen/Laupheim, December 14, 2016 – Sartorius Stedim Cellca based near Ulm in southern Germany, continues on the growth track. At the end of November, the company in its eleventh year since More
New services to enable U.S. biopharmaceutical companies to accelerate development of biosimilar. Goettingen, Germany | Boston, MA, USA – November 10, 2016: Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, opened a new bioanalytical and biosafety testing laboratory yesterday in the major biotech hub of Boston, Massachusetts. This dedicated bioanalytical laboratory More
In-depth profiling of IgG glycosylation coupled with ADCC assays enables generation of robust biosimilar comparability data Glasgow, UK – July 7, 2016: Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, announced the launched of a new Released N-Glycan Assay for the in-depth profiling of IgG glycosylation. This new physico-chemical assay, More